期刊文献+

组蛋白去乙酰化酶抑制剂对宫颈癌细胞的放射增敏作用 被引量:2

Radiosensitizing activity of SAHA on cervical cancer cells
原文传递
导出
摘要 目的探讨组蛋白去乙酰化酶抑制剂SAHA对宫颈癌SiHa细胞的毒性和放射增敏作用。方法 2009年10月至2010年6月在河北联合大学医学院采用MTT法检测SAHA对SiHa细胞的毒性并计算IC50。选择20%IC50的SAHA与放疗联合,克隆形成实验分析SAHA对SiHa细胞的放射增敏作用,采用Sigma Plot 2000 Demo版软件,利用多靶单击模型S=1-(1-eD0/D)n拟合细胞存活曲线,计算放射相关参数和放射增敏比,评价增敏效果。结果 MTT结果显示SAHA对SiHa细胞的毒性反应呈浓度和时间依赖性,SAHA作用SiHa细胞48h的IC50为4.80μmol/L。克隆形成实验结果显示,SAHA联合放疗组细胞的克隆形成率明显低于单独放疗组,二者的平均致死剂量(D0)分别为2.329、1.213,准阈剂量Dq分别为1.721、0.823。放射增敏比(SER)为1.92。结论 SAHA对宫颈癌SiHa细胞有良好的细胞毒性和放射增敏作用。 Objective To observe the radiosensitivity effect of histone deacetylase inhibitor SAHA on human cervical cancer SiHa cells. Methods MTT assay was used to measure the proliferation inhibition of SAHA on SiHa cells from October 2009 to June 2010 in Medical College of Hebei United University. The radiosensitivity effects of SAHA on SiHa cells with the concentration of 20% of IC50 were evaluated by the clonogenic assay. The software Sigma Plot 2000 Demo and the multi-target click model S = 1 - ( 1 - eD0/D) n was used to fit cell survival curve, determining radiation-related i parameters and sensitive enhancement ratio (SER) to evabaate of sensitizing effect. Results ' MTr results showed that toxicity of SAHA on SiHa cell was in a dose and time dependent manner. The IC50 of the proliferation inhibition of SAHA on SiHa cells was 4. 80txmol/L. Cloning experimental results showed that cell survival rate was lower after treatment with the combination of SAHA (20% of IC50) and radiation than the cell survival rate with radiation alone. Both~ the average lethal dose (DO) was 2. 329 and 1. 213 respectively, quasi-threshold dose (Dq) was 1. 721 and 0. 823 respectively. The sensitivity enhancement ratio (SER) was 1.92. Conclusion SAHA has a good cytotoxieity and radiosensitization on Si. Ha cell.
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2012年第1期41-43,共3页 Chinese Journal of Practical Gynecology and Obstetrics
关键词 宫颈肿瘤 SIHA细胞 SAHA 放射增敏 cervical cancer SiHa cells SAHA radiosensitization
  • 相关文献

参考文献10

  • 1Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer[J]. Nat Rev Drug Discov,2002,1 (4) : 287-299.
  • 2Huang BH, Laban M, Leung CH, et al. Inhibition of histone deaeetylase 2 increases apoptosis and p21Cipl/WAF1 expres- sion, independent of histone deacetylase [J]. Cell Death Dif- fer,2005,12(4) :395-404.
  • 3Anton M,Horky M, Kuchtfckov6 S, et al. Immunohistochemical detection of acetylation and phosphorylation of histone H3 in cer- vical smears[ J]. Ceska Gynekol, 2004,69( 1 ) :3-6.
  • 4Tom CK,Assam EO. Clinical potential of histone deacetylase in- hibitors as stand alone therapeutics and in combination with other ehemotherapeutics or radiotherapy for cancer [ J ]. Epigenetics, 2006,1 (3) :121-126.
  • 5Bhupinder SM ,John RJ, Martin HC, et al. FDA approval summa- ry:vorinostat for treatment of advanced primary cutaneous T-cell lymphoma[ J]. The Oncologist, 2007, 2(10) :1247-1252.
  • 6Richon VM, Sdhoff TW, Rifkind RA, et al. Histone deacety- lase inhiNtor selectively induces p21 WAF1 expression and gene- associated histone acetylation [ J ]. Proc Natl Acad Sci USA, 2000,97( 18 ) : 10014-10019.
  • 7Sangeetha SR, Singh N, Vender JR, et al. SuberoyIanilide hydroxamic acid(SAHA) induces growth arrest and apoptosis in pituitary adenoma cells[ J ]. Endocrine, 2009,35 (3) :389-3961.
  • 8Jeyakumar M.tLiu XF, Erdjument-Bromage H, ct al. Phospho- rylation of yroid hormone receptor-associated nuclear receptor corepressor holocomplex by the DNA-dependent protein kinase enhances its histonc deacetylasc activity[ J ]. J Biol Chem, 20071282( 13 ) :9312-9322.
  • 9Zhang F,Zhang T, Teng ZH, et al. Sensitization to gamma-irra- diation-induced cell cycle arrest and apoptosis by the hlstone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells[ J]. Cancer Biol Ther,2009,101:823-831.
  • 10Adimoolam S, Sirisawad M, Chen J, et al. HDAC inhibitor PCI-24781 decreasesRADS1 expression and inhibits homolo- gous recombination [ J]. Proc Natl Acad Sci USA, 2007,104 (49) : 19482-19487.

同被引文献38

  • 1王颖,王生余,侯春梅,徐元基,杜芝燕,于晓妉.组蛋白去乙酰化酶抑制剂SAHA阻断MAPK信号通路并诱导HL-60细胞凋亡[J].中国实验血液学杂志,2007,15(2):267-271. 被引量:3
  • 2Kim DH, Kim M, Kwnn HJ. Histone Deacetylase in carcinogenesis and its inhibitors as anti-cancer agents [ J ]. J Biochem Mol Biol, 2003,36( 1 ) :110-119.
  • 3Mann BS,Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lym- phoma [ J ]. Oncologist, 2007,2 ( 10 ) : 1247-1252.
  • 4Yin D, Ong JM, Hu J, et al. Suberoylanilide hydroxamic acid, a his- tone deaeetylase inhibitor:effects on gene expression and growth of glioma cells in vitro and in vivo[ J]. Clin Cancer Res,2007,13 (3) :1045-1052.
  • 5Jin JS, Tsao TY, Sun PC, et al. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of eye- lin D1 and survivin[ J]. Patho] Oneol Res ,2012,18 ( 3 ) :713-720.
  • 6Munster PN, Troso-Sandoval T, Rosen N, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces dif- ferentiation of human breast cancer cells[ J]. Cancer Res,2001,61 ( 23 ) : 8492-8497.
  • 7Kwon A, Park HJ, Back K, et al. Suberoylanilide hydroxamic acid enhances odontoblast differentiation [ J ]. J Dent Res,2012,91 ( 5 ) : 506-512.
  • 8Gillenwater AM, Zhong M, Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mi- tochondrial and Fas( CD95 ) Signaling in head and neck squamous carcinoma cells[J]. Mol Cancer Ther,2007,6( 11 ) :2967-2975.
  • 9Ruefli AA, Bernhard D,Tainton KM,et al. Suberoylanilide hydrox- amic acid(SAHA) overcomes muhidrug resistance and induces cell death in P-glycoprotein-expressing cells[ J]. Int J Cancer,2002,99 ( 2 ) :292-298.
  • 10Gottesman MM,Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters [ J ]. Nat Rev Cancer, 2002,2 ( 1 ) :48-58.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部